A platform for research: civil engineering, architecture and urbanism
Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy
AbstractAllogeneic tumor cell vaccines provide off‐the‐shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into “zombie cells” capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuvant infection. This causes pseudo‐oncolysis of tumors, transforming them into immunogenic targets for enhanced phagocytosis. It is shown that in postoperative tumor models, localized delivery of premade “zombie cells” through stepwise gelation in resection cavity consolidates tumor surgery. Compared to analogous vaccines lacking “seizing” or “assimilating” capability, “zombie cell” platform effectively mobilizes T cell response against residual tumors, and establishes immunological memory against tumor re‐challenge, showing less susceptibility to immune evasion. Despite using allogeneic sources, “zombie cell” platform functions as generalizable framework to produce long‐term antitumor immunity in different tumor models, showing comparable effect to autologous vaccine. Together, with the potential of off‐the‐shelf availability and personalized relevance to heterogenous tumor antigens, this study suggests an alternative strategy for timely therapy after tumor surgery.
Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy
AbstractAllogeneic tumor cell vaccines provide off‐the‐shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into “zombie cells” capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuvant infection. This causes pseudo‐oncolysis of tumors, transforming them into immunogenic targets for enhanced phagocytosis. It is shown that in postoperative tumor models, localized delivery of premade “zombie cells” through stepwise gelation in resection cavity consolidates tumor surgery. Compared to analogous vaccines lacking “seizing” or “assimilating” capability, “zombie cell” platform effectively mobilizes T cell response against residual tumors, and establishes immunological memory against tumor re‐challenge, showing less susceptibility to immune evasion. Despite using allogeneic sources, “zombie cell” platform functions as generalizable framework to produce long‐term antitumor immunity in different tumor models, showing comparable effect to autologous vaccine. Together, with the potential of off‐the‐shelf availability and personalized relevance to heterogenous tumor antigens, this study suggests an alternative strategy for timely therapy after tumor surgery.
Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy
Advanced Science
Li, Bo (author) / Zhang, Ping (author) / Li, Junlin (author) / Zhou, Rui (author) / Zhou, Minglu (author) / Liu, Chendong (author) / Liu, Xi (author) / Chen, Liqiang (author) / Li, Lian (author)
Advanced Science ; 11
2024-04-01
Article (Journal)
Electronic Resource
English
Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy
Wiley | 2024
|The Identification of Renal Cell Carcinoma as a Target for Allogeneic Based Cancer Immunotherapy
British Library Online Contents | 2002
|Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy
Wiley | 2023
|Wiley | 2021
|